ANDOVER, Mass., Aug. 9, 2021 /PRNewswire/ -- TransMedics
Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology
company that is transforming organ transplant therapy for patients
with end-stage lung, heart, and liver failure, today announced
that on August 4, 2021, TransMedics
granted non-qualified stock options to purchase an aggregate of
160,800 shares of its common stock to five employees as a material
inducement for each employee's entry into employment with
TransMedics. The options were approved by the TransMedics Board of
Directors and were granted in accordance with Nasdaq Listing Rule
5635(c)(4) and pursuant to the TransMedics Group, Inc. Inducement
Plan.
TransMedics granted a non-qualified stock option to Rakesh Godhani, Chief Digital Officer, to
purchase 140,000 shares of TransMedics' common stock and granted
non-qualified stock options to four new non-executive employees to
purchase 20,800 shares of TransMedics' common stock in the
aggregate. The stock options were granted with a per share exercise
price of $27.87, the closing price of
the common stock on the Nasdaq Global Market on the date of grant.
Twenty-five percent of the shares subject to each option will vest
on the first yearly anniversary of the date of the employee's start
of employment, with the remainder vesting in equal monthly
installments over the subsequent three year period, subject to the
employee's continued service with the Company through the
applicable vesting date. The options have a 10-year term and are
subject to the terms of the TransMedics Group, Inc. Inducement
Plan.
About TransMedics Group, Inc.
TransMedics is the
world's leader in portable extracorporeal warm perfusion and
assessment of donor organs for transplantation. Headquartered in
Andover, Massachusetts, the
company was founded to address the unmet need for more and better
organs for transplantation and has developed technologies to
preserve organ quality, assess organ viability prior to transplant,
and potentially increase the utilization of donor organs for the
treatment of end-stage heart, lung, and liver failure.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301351363.html
SOURCE TransMedics Group, Inc.